CLINICAL_TRIALS
trial_result
· 2018-07-26
Clinical Trial Update: Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis [Phase 3]
Summary
Extension study assessing long-term safety of BIBF 1120 (nintedanib) in idiopathic pulmonary fibrosis after completion of prior trials.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Idiopathic Pulmonary Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2018-07-26